What is Avea?
Founded in 2021 and operating from London, the United Kingdom, and Switzerland, Avea is a notable player in the longevity supplement market. The company focuses on developing and branding products aimed at enhancing healthy aging and rejuvenation. Its establishment in a competitive landscape, coupled with significant enterprise-level funding, positions Avea as a company with ambitious growth plans and a commitment to scientific innovation in the wellness industry.
How much funding has Avea raised?
Avea has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2023): $5M with participation from Maximon
Key Investors in Avea
Maximon
Maximon is a Swiss-based company builder specializing in the creation of scalable, science-based businesses focused on healthy aging and rejuvenation. They actively support entrepreneurs in the longevity sector, fostering innovation and connecting stakeholders within the ecosystem.
What's next for Avea?
With a substantial recent strategic investment, Avea is poised for accelerated growth and market expansion. This capital infusion is likely to fuel further research and development, enhance manufacturing capabilities, and broaden its distribution channels. The company's focus on the burgeoning longevity market suggests a strategic intent to capture a significant share by offering science-backed supplements. Future developments may include new product lines, strategic partnerships, and increased global market penetration, solidifying its position as a key enterprise in the healthy aging sector.
See full Avea company page
